ECSP19030134A - Compuesto de piridina - Google Patents
Compuesto de piridinaInfo
- Publication number
- ECSP19030134A ECSP19030134A ECSENADI201930134A ECDI201930134A ECSP19030134A EC SP19030134 A ECSP19030134 A EC SP19030134A EC SENADI201930134 A ECSENADI201930134 A EC SENADI201930134A EC DI201930134 A ECDI201930134 A EC DI201930134A EC SP19030134 A ECSP19030134 A EC SP19030134A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyridine compound
- pharmaceutically acceptable
- acceptable salt
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención tiene relación con un compuesto que tiene acción inhibidora de quinasa RET o una sal farmacéuticamente aceptable del mismo, útil en el tratamiento de enfermedades como cáncer. En particular un compuesto representado por la siguiente fórmula general (I) como se define en este documento: [Fórmula I] (ver figura) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016191725A JP2018052878A (ja) | 2016-09-29 | 2016-09-29 | ピリジン化合物 |
PCT/GB2017/052913 WO2018060714A1 (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19030134A true ECSP19030134A (es) | 2019-08-30 |
Family
ID=60020249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201930134A ECSP19030134A (es) | 2016-09-29 | 2019-04-29 | Compuesto de piridina |
Country Status (32)
Country | Link |
---|---|
US (2) | US10851092B2 (es) |
EP (2) | EP3519398B1 (es) |
JP (2) | JP2018052878A (es) |
KR (1) | KR102520543B1 (es) |
CN (2) | CN113788824A (es) |
AU (2) | AU2017335242C1 (es) |
BR (1) | BR112019006047A2 (es) |
CA (1) | CA3035860A1 (es) |
CL (1) | CL2019000844A1 (es) |
CO (1) | CO2019004034A2 (es) |
CY (1) | CY1123988T1 (es) |
DK (1) | DK3519398T3 (es) |
EA (1) | EA037103B1 (es) |
EC (1) | ECSP19030134A (es) |
ES (1) | ES2868748T3 (es) |
HR (1) | HRP20210447T1 (es) |
HU (1) | HUE054824T2 (es) |
IL (1) | IL265630B (es) |
LT (1) | LT3519398T (es) |
MA (2) | MA54910A (es) |
MD (1) | MD3519398T2 (es) |
MX (1) | MX2019003747A (es) |
PE (1) | PE20190805A1 (es) |
PH (1) | PH12019500480A1 (es) |
PL (1) | PL3519398T3 (es) |
PT (1) | PT3519398T (es) |
RS (1) | RS61640B1 (es) |
SG (1) | SG11201901937WA (es) |
SI (1) | SI3519398T1 (es) |
UA (1) | UA123964C2 (es) |
WO (1) | WO2018060714A1 (es) |
ZA (1) | ZA201902232B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ742351A (en) | 2015-11-02 | 2023-03-31 | Blueprint Medicines Corp | Inhibitors of ret |
JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
MX2022005991A (es) * | 2019-11-18 | 2022-06-17 | Chugai Pharmaceutical Co Ltd | Farmaco combinado. |
CN113121524B (zh) | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021164741A1 (zh) * | 2020-02-20 | 2021-08-26 | 南京明德新药研发有限公司 | 苯基双酰胺类化合物 |
JP7461605B2 (ja) | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
WO2022238706A1 (en) | 2021-05-14 | 2022-11-17 | Bp Asset Viii, Inc. | Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer |
US20230233691A1 (en) | 2021-10-22 | 2023-07-27 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
CN115090331B (zh) * | 2022-07-21 | 2023-05-16 | 扬州大学 | 超分子手性催化剂、其制备方法及其催化d-a反应的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
JP2009528335A (ja) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
EP1994024A2 (en) | 2006-03-02 | 2008-11-26 | AstraZeneca AB | Quinoline derivatives |
WO2007113565A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
WO2007113548A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
AU2010218748B2 (en) * | 2009-02-27 | 2015-03-26 | Teijin Limited | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst |
JP2013502429A (ja) | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
NZ598588A (en) | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
EP2560652A4 (en) | 2010-04-23 | 2013-08-14 | Kineta Inc | ANTIVIRAL CONNECTIONS |
US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
AU2013289938A1 (en) | 2012-07-13 | 2015-01-29 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
BR112015023618A2 (pt) | 2013-03-15 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | derivados de piridina como inibidores de quinase reorganizada durante a transfecção (ret) |
WO2015031613A1 (en) * | 2013-08-30 | 2015-03-05 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
JPWO2015163435A1 (ja) * | 2014-04-24 | 2017-04-20 | 田辺三菱製薬株式会社 | 新規2−アミノ−ピリジン及び2−アミノ−ピリミジン誘導体及びその医薬用途 |
CA2960730A1 (en) * | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
RS58813B1 (sr) * | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
EP3206689B1 (en) | 2014-10-14 | 2021-12-08 | La Jolla Institute of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
CN104844589B (zh) | 2014-12-26 | 2018-04-20 | 中国科学院合肥物质科学研究院 | 一种pi3k激酶抑制剂 |
US10202365B2 (en) * | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
-
2016
- 2016-09-29 JP JP2016191725A patent/JP2018052878A/ja active Pending
-
2017
- 2017-09-28 US US16/337,896 patent/US10851092B2/en active Active
- 2017-09-28 KR KR1020197012323A patent/KR102520543B1/ko active IP Right Grant
- 2017-09-28 HU HUE17780169A patent/HUE054824T2/hu unknown
- 2017-09-28 JP JP2019516670A patent/JP7098609B2/ja active Active
- 2017-09-28 CN CN202111188408.2A patent/CN113788824A/zh active Pending
- 2017-09-28 EA EA201990833A patent/EA037103B1/ru unknown
- 2017-09-28 MA MA054910A patent/MA54910A/fr unknown
- 2017-09-28 DK DK17780169.3T patent/DK3519398T3/da active
- 2017-09-28 CA CA3035860A patent/CA3035860A1/en active Pending
- 2017-09-28 EP EP17780169.3A patent/EP3519398B1/en active Active
- 2017-09-28 MA MA46337A patent/MA46337B1/fr unknown
- 2017-09-28 PT PT177801693T patent/PT3519398T/pt unknown
- 2017-09-28 SG SG11201901937WA patent/SG11201901937WA/en unknown
- 2017-09-28 MD MDE20190863T patent/MD3519398T2/ro unknown
- 2017-09-28 SI SI201730683T patent/SI3519398T1/sl unknown
- 2017-09-28 WO PCT/GB2017/052913 patent/WO2018060714A1/en unknown
- 2017-09-28 ES ES17780169T patent/ES2868748T3/es active Active
- 2017-09-28 BR BR112019006047A patent/BR112019006047A2/pt not_active Application Discontinuation
- 2017-09-28 MX MX2019003747A patent/MX2019003747A/es unknown
- 2017-09-28 UA UAA201904549A patent/UA123964C2/uk unknown
- 2017-09-28 PE PE2019000730A patent/PE20190805A1/es unknown
- 2017-09-28 CN CN201780074582.XA patent/CN110036007B/zh active Active
- 2017-09-28 LT LTEP17780169.3T patent/LT3519398T/lt unknown
- 2017-09-28 RS RS20210332A patent/RS61640B1/sr unknown
- 2017-09-28 EP EP21151210.8A patent/EP3828178A1/en not_active Withdrawn
- 2017-09-28 AU AU2017335242A patent/AU2017335242C1/en active Active
- 2017-09-28 PL PL17780169T patent/PL3519398T3/pl unknown
-
2019
- 2019-03-05 PH PH12019500480A patent/PH12019500480A1/en unknown
- 2019-03-26 IL IL265630A patent/IL265630B/en unknown
- 2019-03-28 CL CL2019000844A patent/CL2019000844A1/es unknown
- 2019-04-09 ZA ZA2019/02232A patent/ZA201902232B/en unknown
- 2019-04-23 CO CONC2019/0004034A patent/CO2019004034A2/es unknown
- 2019-04-29 EC ECSENADI201930134A patent/ECSP19030134A/es unknown
-
2020
- 2020-11-24 US US17/103,515 patent/US20210163464A1/en not_active Abandoned
-
2021
- 2021-03-17 CY CY20211100228T patent/CY1123988T1/el unknown
- 2021-03-17 HR HRP20210447TT patent/HRP20210447T1/hr unknown
- 2021-11-03 AU AU2021261899A patent/AU2021261899A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19030134A (es) | Compuesto de piridina | |
ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
PE20151654A1 (es) | Inhibidores de cdc7 | |
CO2017012067A2 (es) | Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste | |
CO2017004784A2 (es) | Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a | |
CU20160195A7 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
GT201600232A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
AR115865A2 (es) | Compuestos terapéuticos | |
UY35317A (es) | Compuesto de ciclopropanoamina |